Several studies have evaluated the efficacy of this treatment depending on several conditions as extend of tumor resection [5,6,7,8,9,10,11], age [12], the methylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter gene [13], dose of temozolomide [14,15,16,17,18,19,20], the addition of new agents [21,22,23], or the device tumor treating fields [24,25,26,27,28,29,30], that in fact is the only modification that has proven to increase survival. The gene discussed is MGMT; the disease is neoplasm.